• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    5/6/24 12:31:16 PM ET
    $AFIB
    $CMMB
    $EYPT
    $GLYC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFIB alert in real time by email

    Gainers

    • NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 35.61% to $1.98. The company's market cap stands at $6.3 million.
    • Outset Medical (NASDAQ:OM) stock rose 26.15% to $3.96. The company's market cap stands at $204.8 million.
    • Nanoviricides (AMEX:NNVC) stock moved upwards by 25.66% to $1.42. The market value of their outstanding shares is at $16.7 million.
    • Chemomab Therapeutics (NASDAQ:CMMB) stock rose 22.16% to $0.9. The market value of their outstanding shares is at $12.8 million.
    • Titan Pharma (NASDAQ:TTNP) shares moved upwards by 22.09% to $8.4. The market value of their outstanding shares is at $7.6 million.

    Losers

    • Lyra Therapeutics (NASDAQ:LYRA) shares decreased by 86.3% to $0.55 during Monday's regular session. The market value of their outstanding shares is at $33.6 million. As per the news, the Q1 earnings report came out 4 days ago.
    • GlycoMimetics (NASDAQ:GLYC) stock declined by 79.04% to $0.38. The market value of their outstanding shares is at $24.7 million.
    • EyePoint Pharmaceuticals (NASDAQ:EYPT) shares declined by 39.37% to $11.97. The market value of their outstanding shares is at $623.4 million.
    • Acutus Medical (NASDAQ:AFIB) stock fell 27.1% to $0.11. The company's market cap stands at $3.1 million.
    • Integra Lifesciences (NASDAQ:IART) shares declined by 20.46% to $22.98. The company's market cap stands at $1.8 billion. The company's, Q1 earnings came out today.
    • Helius Medical Tech (NASDAQ:HSDT) shares fell 14.81% to $2.44. The company's market cap stands at $2.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB
    $CMMB
    $EYPT
    $GLYC

    CompanyDatePrice TargetRatingAnalyst
    NanoViricides Inc.
    $NNVC
    12/16/2025Buy
    Alliance Global Partners
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    EyePoint Inc.
    $EYPT
    6/17/2025$28.00Outperform
    RBC Capital Mkts
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    Integra LifeSciences Holdings Corporation
    $IART
    3/31/2025Hold → Buy
    Argus
    GlycoMimetics Inc.
    $GLYC
    3/21/2025Overweight
    Cantor Fitzgerald
    EyePoint Inc.
    $EYPT
    1/7/2025$33.00Buy
    Citigroup
    Integra LifeSciences Holdings Corporation
    $IART
    12/2/2024$25.00 → $20.00Underweight
    Morgan Stanley
    More analyst ratings

    $AFIB
    $CMMB
    $EYPT
    $GLYC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

    MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin

    3/17/26 7:45:00 AM ET
    $IART
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

    Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA).FDA has advised NRx in written correspondence that it has not identified any bioequivalence deficiencies in the Company's Preservative-Free Ketamine product. This communication is deemed preliminary until final supervisory review.NRx continues to anticipate an FDA GDUFA decision on its ANDA application in Summer 2026 as previously announced.The ANDA process is focused on offering a preservative-free alternative in the existing ketamine market through the FDA Office of Generic Drugs and is separate from NRx's path to a New Drug Application to use ketamine in the

    3/17/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $CMMB
    $EYPT
    $GLYC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Duker Jay S. bought $19,724 worth of shares (1,500 units at $13.15) (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    3/16/26 4:12:55 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP & PRESIDENT, INTERNATIONAL Singh Harvinder converted options into 20,138 shares and covered exercise/tax liability with 6,652 shares, increasing direct ownership by 61% to 35,422 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    3/12/26 6:10:55 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    EVP & President, CSS Mcbreen Michael J. covered exercise/tax liability with 9,601 shares, decreasing direct ownership by 14% to 60,743 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    3/12/26 5:18:04 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $AFIB
    $CMMB
    $EYPT
    $GLYC
    SEC Filings

    View All

    SEC Form 6-K filed by Chemomab Therapeutics Ltd.

    6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

    3/19/26 8:05:05 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Lyra Therapeutics Inc.

    8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

    3/16/26 4:30:39 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by EyePoint Inc.

    10-K - EyePoint, Inc. (0001314102) (Filer)

    3/5/26 4:06:01 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AFIB
    $CMMB
    $EYPT
    $GLYC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AFIB
    $CMMB
    $EYPT
    $GLYC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on NanoViricides

    Alliance Global Partners initiated coverage of NanoViricides with a rating of Buy

    12/16/25 8:59:58 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on NRx Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/8/25 8:58:39 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on EyePoint Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00

    6/17/25 7:49:38 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Duker Jay S. bought $19,724 worth of shares (1,500 units at $13.15) (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    3/16/26 4:12:55 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Graves Jeffrey A bought $102,150 worth of shares (9,000 units at $11.35), increasing direct ownership by 28% to 41,086 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    11/6/25 4:05:46 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Director Zaderej Karen L. bought $59,000 worth of shares (10,000 units at $5.90), increasing direct ownership by 38% to 36,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/19/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AFIB
    $CMMB
    $EYPT
    $GLYC
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $CMMB
    $EYPT
    $GLYC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

    SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/29/24 3:04:59 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $CMMB
    $EYPT
    $GLYC
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance

    PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) --  Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.Adjusted earnings per diluted share were $0.83, compared to $0.97 in the fourth quarter of 2024. Full-Year 2025 Reported revenues were $1,635.2 million, representing an increase of 1.5% on a reported basis and

    2/26/26 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

    WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/i8pzi8wg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A w

    2/25/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AFIB
    $CMMB
    $EYPT
    $GLYC
    Leadership Updates

    Live Leadership Updates

    View All

    Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

    MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin

    3/17/26 7:45:00 AM ET
    $IART
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EyePoint Appoints Michael Campbell as Chief Commercial Officer

    – Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Michael Campbell has been appointed Chief Commercial Officer. Mr. Campbell, an experienced commercial leader with a proven track record of successful product launches and oversight of

    2/18/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials